GeoVax Labs, Inc. announced that its Chief Medical Officer and clinical collaborators will present data highlighting the immune responses induced by the Company's next-generation COVID-19 vaccine, GEO-CM04S1, in immunocompromised patients with hematologic malignancies at two international scientific conferences in September. The presentations will focus on clinical evaluations showing the vaccine's effectiveness in vulnerable populations where current authorized COVID-19 vaccines have proven insufficient.
The data will be presented at the 6th ESCMID Conference on Vaccines in Lisbon, Portugal, from September 10-13, 2025, where Chief Medical Officer Kelly T. McKee, Jr., MD, MPH will deliver a poster presentation titled "GEO-CM04S1, a multi-antigen COVID-19 vaccine for immunocompromised individuals: clinical evaluation to date." For more information on the conference, please visit https://www.escmid.org/congress-events/6th-escmid-conference-on-vaccines.
Additional data will be presented at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL 2025) in Krakow, Poland, from September 12-15, 2025. Professor Alexey V. Danilov, MD, PhD from City of Hope National Medical Center will present a poster showing that the MVA-based GEO-CM04S1 vaccine results in improved cellular immune response in patients with chronic lymphocytic leukemia compared with mRNA-based vaccines, based on initial results from a Phase II randomized study.
The significance of these findings lies in addressing a critical healthcare gap. Immunocompromised patients, particularly those with hematologic malignancies, have shown inadequate responses to current COVID-19 vaccines, leaving them vulnerable to severe outcomes. GEO-CM04S1 represents a multi-antigen approach designed to provide broader protection against COVID-19 variants through both antibody and cellular immune responses.
For more information on the iwCLL conference, please visit https://www.iwcll.org/events/xxi-iwcll-12-15-september-2025-krakow-poland/. The vaccine is currently in three Phase 2 clinical trials evaluating its effectiveness as a primary vaccine for immunocompromised patients, a booster for CLL patients, and a more robust booster for healthy patients previously vaccinated with mRNA vaccines.
This development matters because it addresses the ongoing need for effective COVID-19 protection in vulnerable populations who remain at high risk despite existing vaccination efforts. The research could lead to improved outcomes for millions of immunocompromised individuals worldwide and represents an important advancement in pandemic preparedness and vaccine development strategies.
